Beam Therapeutics announced updated biomarker data from its BEACON Phase 1/2 trial of risto-cel, a gene-edited cell therapy for sickle cell disease (SCD), to be presented at EHA2026. The data highlight risto-cel's ability to restore red blood cell health and function, with improvements in sickling and blood flow parameters comparable to sickle cell trait. This supports risto-cel's potential as a one-time treatment to increase fetal hemoglobin and reduce severe complications in SCD patients. The therapy is still under clinical evaluation, with further data expected to clarify its long-term benefits.
Li Auto has integrated Arteris' FlexNoC 5 network-on-chip IP and Magillem software into its proprietary autonomous driving SoCs for the new L9 Livis SUV. This technology supports AI data movement and integration, enabling the vehicle to perform 2,560...
Arteris, Inc. announced its system IP technology is adopted by Li Auto for its new L9 Livis flagship SUV, integrating the Mach M100 autonomous driving SoC. This collaboration enhances AI data movement and system efficiency, meeting high performance, ...
Durantic, founded by former Meta and Hudson River Trading engineers, has launched a managed infrastructure layer to operate AI workloads across diverse GPU environments. The company addresses the growing complexity of AI infrastructure, which spans h...
Webull Corp. has introduced Vega Analyst, an AI-powered research tool that provides customized, real-time stock analysis based on user-selected research areas like fundamentals, valuation, and technical trends. This tool helps investors better unders...
Brady Corporation announced a regular dividend of $0.245 per share for its Class A Common Stock. The dividend will be paid on July 31, 2026, to shareholders of record as of July 10, 2026. This move reflects Brady's ongoing commitment to returning val...
